Evidence map›Paper›PMID 42177400›Full record

ArticleBMC gastroenterology2026

Association of metabolic vulnerability index with various chronic liver diseases and mortality: a large prospective cohort study.

Zihan Qin, Kaiqi Yang, Zheng Liang, Le Gao, Yifei Liu, Jiafei Peng, Hongtao Wei, Shutian Zhang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Zihan Qin *Department of Gastroenterology, Beijing Friendship Hospital, Capital Medical University; State Key Laboratory of Digestive Health; National Clinical Research Center for Digestive Disease; Beijing Key Laboratory of Early Gastrointestinal Cancer Medicine and Medical Devices, 100050, Beijing, China.
Kaiqi Yang *Department of Gastroenterology, Beijing Friendship Hospital, Capital Medical University; State Key Laboratory of Digestive Health; National Clinical Research Center for Digestive Disease; Beijing Key Laboratory of Early Gastrointestinal Cancer Medicine and Medical Devices, 100050, Beijing, China.
Zheng Liang *Department of Gastroenterology, Beijing Friendship Hospital, Capital Medical University; State Key Laboratory of Digestive Health; National Clinical Research Center for Digestive Disease; Beijing Key Laboratory of Early Gastrointestinal Cancer Medicine and Medical Devices, 100050, Beijing, China.
Le GaoDepartment of Gastroenterology, Beijing Friendship Hospital, Capital Medical University; State Key Laboratory of Digestive Health; National Clinical Research Center for Digestive Disease; Beijing Key Laboratory of Early Gastrointestinal Cancer Medicine and Medical Devices, 100050, Beijing, China.
Yifei LiuHebei Medical University, Shijiazhuang, 050017, China.
Jiafei PengDepartment of Gastroenterology, Beijing Friendship Hospital, Capital Medical University; State Key Laboratory of Digestive Health; National Clinical Research Center for Digestive Disease; Beijing Key Laboratory of Early Gastrointestinal Cancer Medicine and Medical Devices, 100050, Beijing, China.
Hongtao WeiDepartment of Gastroenterology, Beijing Friendship Hospital, Capital Medical University; State Key Laboratory of Digestive Health; National Clinical Research Center for Digestive Disease; Beijing Key Laboratory of Early Gastrointestinal Cancer Medicine and Medical Devices, 100050, Beijing, China. wht001@mail.ccmu.edu.cn.
Shutian ZhangDepartment of Gastroenterology, Beijing Friendship Hospital, Capital Medical University; State Key Laboratory of Digestive Health; National Clinical Research Center for Digestive Disease; Beijing Key Laboratory of Early Gastrointestinal Cancer Medicine and Medical Devices, 100050, Beijing, China.

Funding

Beijing Tongzhou District Science and Technology Plan Projects KJ2024CX033Research and Translational Application of Clinical Characteristic Diagnostic and Treatment Techniques in Capital City Z221100007422002
6 · The paper itself

Abstract

backgroundThe association between metabolic vulnerability index (MVX), a composite biomarker integrating inflammatory and metabolic pathways, and chronic liver diseases (CLDs) is still unclear.

methodsThis prospective cohort study included 255,171 participants from the UK Biobank, with a median follow-up period of 13.71 years. Multivariable-adjusted cox proportional hazards models, restricted cubic splines (RCS) and sensitivity analyses were used to evaluate the association between MVX and CLDs.

resultsThis study showed that higher levels of MVX (Q4 vs Q1) significantly increased the risk of CLDs after adjusted by socio-demographic and health status factors (all P < 0.05): cirrhosis (HR = 1.60, 95%CI:1.38-1.86), alcoholic-related liver disease (HR = 1.34, 95%CI:1.07-1.68), autoimmune liver disease (HR = 1.35, 95%CI:1.12-1.62), liver and biliary tract cancer (HR = 1.32, 95%CI:1.05-1.66), liver disease-related death (HR = 2.11, 95%CI:1.59-2.80), and all-cause mortality (HR = 1.17, 95%CI:1.13-1.21). No association was found between MVX and viral hepatitis. RCS and threshold analysis showed a reverse L-shaped association between MVX and cirrhosis and liver-related deaths, a linearly increasing association with AILD and LBC, and a J-shaped association with ALD and all-cause mortality. Subgroups analysis and sensitivity analyses demonstrated stable correlation between MVX and CLDs and death events.

conclusionMVX is a promising indicator for independently predicting CLD events, liver-related mortality, and all-cause mortality. As a marker of metabolic-inflammatory dysregulation, MVX may enable early identification of high-risk individuals for targeted primary prevention of CLDs.

Indexed as

Liver DiseasesAgedBiomarkersChronic DiseaseFemaleHumansMaleMiddle AgedProportional Hazards ModelsProspective StudiesRisk FactorsUnited KingdomBiomarkersChronic liver diseaseCirrhosisLiver-related mortalityMetabolic-inflammatory disordersMetabolic vulnerability index

Identifiers

PMID42177400
PMCPMC13374217

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.